Design Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.05 21:45
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.3, beating the estimate of USD -0.34.

EBIT: As of FY2025 Q3, the actual value is USD -21.63 M.

Segment Revenue

  • Design Therapeutics, Inc. operates in one segment focused on utilizing its GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Operational Metrics

  • Net Loss: For the three months ended September 30, 2025, the net loss was - $16,997,000, compared to - $13,039,000 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was - $53,795,000, compared to - $35,937,000 for the same period in 2024.
  • Total Operating Expenses: For the three months ended September 30, 2025, total operating expenses were $19,311,000, compared to $16,246,000 for the same period in 2024. For the nine months ended September 30, 2025, total operating expenses were $61,298,000, compared to $45,689,000 for the same period in 2024.
  • Research and Development Expenses: For the three months ended September 30, 2025, research and development expenses were $14,589,000, compared to $11,876,000 for the same period in 2024. For the nine months ended September 30, 2025, research and development expenses were $45,704,000, compared to $32,193,000 for the same period in 2024.
  • General and Administrative Expenses: For the three months ended September 30, 2025, general and administrative expenses were $4,722,000, compared to $4,370,000 for the same period in 2024. For the nine months ended September 30, 2025, general and administrative expenses were $15,594,000, compared to $13,496,000 for the same period in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $42,392,000, compared to - $33,245,000 for the same period in 2024.
  • Net Cash Provided by Investing Activities: For the nine months ended September 30, 2025, net cash provided by investing activities was $34,496,000, compared to $42,123,000 for the same period in 2024.
  • Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $421,000, compared to $250,000 for the same period in 2024.

Future Outlook and Strategy

  • Core Business Focus: Design Therapeutics, Inc. plans to continue the development of its FA, FECD, DM1, and HD programs and other discovery programs, with an emphasis on advancing product candidates into and through clinical development. The company anticipates providing updates on its RESTORE-FA trial and Phase 2 biomarker trial in the second half of 2026.
  • Funding Requirements: The company believes its existing cash, cash equivalents, and investments will be sufficient to fund its planned operating expenses and capital expenditure requirements for more than the next 12 months following the date of the report.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.